Skip to content

Research at St Andrews

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Research output: Contribution to journalArticle

Author(s)

Conor Duncan Tweed, Genevieve Helen Wills, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Cheryl E. Louw, Timothy D. McHugh, Carl Mendel, Sarah Meredith, Lerato Mohapi, Michael E. Murphy, Stephen Murray, Sara Murthy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha Singh, M. Spigelman, S. H. Gillespie

School/Research organisations

Abstract

Background:  Drug-induced liver injury (DILI) is a common complication of tuberculosis treatment. We utilised data from the REMoxTB clinical trial to describe the incidence of predisposing factors and the natural history in patients with liver enzyme levels elevated in response to tuberculosis treatment.

Methods: Patients received either standard tuberculosis treatment (2EHRZ/4HR), or a 4-month regimen in which moxifloxacin replaced either ethambutol (isoniazid arm, 2MHRZ/2MHR) or isoniazid (ethambutol arm, 2EMRZ/2MR). Hepatic enzymes were measured at 0, 2, 4, 8, 12 and 17 weeks and as clinically indicated during reported adverse events. Patients included were those receiving at least one dose of drug and with two or more hepatic enzyme measurements.

Results: A total of 1928 patients were included (639 2EHRZ/4HR, 654 2MHRZ/2MHR and 635 2EMRZ/2MR). DILI was defined as peak alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (5 × ULN) or ALT ≥ 3 × ULN with total bilirubin > 2 × ULN. DILI was identified in 58 of the 1928 (3.0%) patients at a median time of 28 days (interquartile range IQR 14–56). Of 639 (6.4%) patients taking standard tuberculosis therapy, 41 experienced clinically significant enzyme elevations (peak ALT ≥ 3 × ULN). On standard therapy, 21.1% of patients aged >55 years developed a peak ALT/aspartate aminotransferase (AST) ≥ 3 × ULN (p = 0.01) and 15% of HIV-positive patients experienced a peak ALT/AST ≥ 3 × ULN compared to 9% of HIV-negative patients (p = 0.160). The median peak ALT/AST was higher in isoniazid-containing regimens vs no-isoniazid regimens (p < 0.05), and lower in moxifloxacin-containing arms vs no-moxifloxacin arms (p < 0.05). Patients receiving isoniazid reached a peak ALT ≥ 3 × ULN 9.5 days earlier than those on the ethambutol arm (median time of 28 days vs 18.5 days). Of the 67 Asian patients with a peak ALT/AST ≥ 3 × ULN, 57 (85.1%) were on an isoniazid-containing regimen (p = 0.008).

Conclusions: Our results provide evidence of the risk of DILI in tuberculosis patients on standard treatment. Older patients on standard therapy, HIV-positive patients, Asian patients and those receiving isoniazid were at higher risk of elevated enzyme levels. Monitoring hepatic enzymes during the first 2 months of standard therapy detected approximately 75% of patients with a peak enzyme elevation ≥3 × ULN, suggesting this should be a standard of care. These results provide evidence for the potential of moxifloxacin in hepatic sparing.
Close

Details

Original languageEnglish
Article number46
Number of pages10
JournalBMC Medicine
Volume16
DOIs
StatePublished - 28 Mar 2018

    Research areas

  • Tuberculosis, Hepatotoxicity, Drug-induced liver injury, Treatment monitoring

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  2. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  3. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. & Simonsson, U. S. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

  4. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R. 18 Jun 2018 In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis

    Murthy, S. E., Chatterjee, F., Crook, A., Dawson, R., Mendel, C., Murphy, M. E., Murray, S. R., Nunn, A. J., Phillips, P. P. J., Singh, K. P., McHugh, T. D., Gillespie, S. H. & on behalf of the REMoxTB Consortium 21 May 2018 In : BMC Medicine. 16, 11 p., 73

    Research output: Contribution to journalArticle

  2. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

    Phillips, P. P. J., Mendel, C. M., Nunn, A. J., McHugh, T. D., Crook, A. M., Hunt, R., Bateson, A. & Gillespie, S. H. 24 Nov 2017 In : BMC Medicine. 15, 9 p., 207

    Research output: Contribution to journalArticle

  3. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

    Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M. 26 Jun 2017 In : BMC Medicine. 15, 12 p., 118

    Research output: Contribution to journalArticle

  4. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

    Murphy, M. E., Phillips, P. P. J., Mendel, C. M., Bongard, E., Bateson, A. L. C., Hunt, R., Murthy, S., Singh, K. P., Brown, M., Crook, A. M., Nunn, A. J., Meredith, S. K., Lipman, M., McHugh, T. D., Gillespie, S. H. & on behalf of the REMoxTB Consortium 27 Oct 2017 In : BMC Medicine. 15, 10 p., 192

    Research output: Contribution to journalArticle

ID: 252649357